Physician profile
Daniel Emesiani
NPI 1407387533
$6,502.00
in general payments reported to CMS, 2019-2025
22 companies · $2,353 in 2025
The $2,353 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $215 · 2023: $1,548 · 2024: $2,385 · 2025: $2,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,188 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,187.56 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,134.15 | 2022-2025 | |
| Amgen INC. | $1,030.00 | 2023-2025 | Krystexxa, Enbrel, Tavneos |
| Ucb, INC. | $734.91 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $543.24 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $471.22 | 2022-2025 | Saphnelo |
| Pfizer INC. | $312.55 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $244.32 | 2023-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $220.49 | 2022-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $214.81 | 2022-2025 | |
| Sandoz INC. | $115.88 | 2023-2024 | Hyrimoz |
| Lilly USA, LLC | $72.44 | 2023 | Taltz |
| Horizon Therapeutics Plc | $66.75 | 2022-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.24 | 2023-2024 | Cyltezo |
| Mallinckrodt Hospital Products INC. | $45.41 | 2023 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $43.24 | 2023 | Orencia |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $41.72 | 2023-2024 | Idacio |
| Genentech USA, INC. | $41.64 | 2024-2025 | Actemra |
| Janssen Scientific Affairs, LLC | $37.23 | 2025 | Tremfya |
| Scilex Pharmaceuticals INC. | $34.28 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $19.32 | 2023 | Crysvita |
| Aimmune Therapeutics, INC. | $16.90 | 2024 | |
| Biogen, INC. | $15.26 | 2024 | Tofidence |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Emesiani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.